December 18, 2024
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
December 3, 2024
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
November 26, 2024
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
November 6, 2024
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
November 6, 2024
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 1, 2024
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
September 26, 2024
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
September 5, 2024
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
September 4, 2024
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
September 3, 2024
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Displaying 1 - 10 of 32